Characteristics, Biological Activities, Synthesis, and Methods for the Determination of Brexpiprazole in Different Matrices / Alankar Shrivastava, Ashu Mittal, Rakhi Khabiya, GP Choudhary, Gajanan N. Darwhekar
Background: Brexpiprazole (BRZ) is a "third-generation" antipsychotic dopaminergic (D2) and 5HT 1A (serotonin) partial agonist, approved in July 2015 by the US Food and Drug Administration for the treatment of the major depressive disorder (MDD) other than schizophrenia in adults. Antipsychotics are known to produce extrapyramidal effects as side effects. The recent development in this segment is of piperazine-based antipsychotic BRZ, which is more specific towards indented indications (depression) and has fewer side effects. Objective: To critically review the different analytical methods available in the literature. Methods: Eight spectrophotometry-based studies, nineteen chromatography-based studies, and two other method-based studies were found in the literature search. A brief discussion on pharmacokinetics and the mechanism of action is also included. Conclusion: This review can be used for the development of more robust and suitable analytical methods for the determination of drugs in different matrices. A brief discussion concerning the approach towards the advancement of green analytical methods is likewise one of the points of this review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current pharmaceutical analysis - 18(2022), 8, Seite 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shrivastava, Alankar [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (12 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011170689 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011170689 | ||
| 003 | DE-627 | ||
| 005 | 20231128145737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011170689 | ||
| 035 | |a (KFL)prod_DARH_.722AE0C9E0187A08F8096342211545545A51869A | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Shrivastava, Alankar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics, Biological Activities, Synthesis, and Methods for the Determination of Brexpiprazole in Different Matrices |c Alankar Shrivastava, Ashu Mittal, Rakhi Khabiya, GP Choudhary, Gajanan N. Darwhekar |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (12 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Brexpiprazole (BRZ) is a "third-generation" antipsychotic dopaminergic (D2) and 5HT 1A (serotonin) partial agonist, approved in July 2015 by the US Food and Drug Administration for the treatment of the major depressive disorder (MDD) other than schizophrenia in adults. Antipsychotics are known to produce extrapyramidal effects as side effects. The recent development in this segment is of piperazine-based antipsychotic BRZ, which is more specific towards indented indications (depression) and has fewer side effects. Objective: To critically review the different analytical methods available in the literature. Methods: Eight spectrophotometry-based studies, nineteen chromatography-based studies, and two other method-based studies were found in the literature search. A brief discussion on pharmacokinetics and the mechanism of action is also included. Conclusion: This review can be used for the development of more robust and suitable analytical methods for the determination of drugs in different matrices. A brief discussion concerning the approach towards the advancement of green analytical methods is likewise one of the points of this review | ||
| 700 | 1 | |a Mittal, Ashu |e verfasserin |4 aut | |
| 700 | 1 | |a Khabiya, Rakhi |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhary, GP |e verfasserin |4 aut | |
| 700 | 1 | |a Darwhekar, Gajanan N. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical analysis |d Sharjah, U.A.E. : Bentham Science Publ., 2005 |g 18(2022), 8, Seite 12 |h Online-Ressource |w (DE-627)KFL000006440 |w (DE-600)2216923-4 |w (DE-576)306832917 |x 1875-676X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:8 |g pages:12 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4129&volume=18&issue=8&spage=765 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 8 |h 12 | ||